Oxaliplatin and targeted adjunct-chemotherapy for bowel cancer through DNA-binding: Causal involvement of ROS?

Journal of Applied Therapeutic Research

Volumn 5, Issue 3, 2005, Pages 24-31

  Wiseman, Alan ^a   Goldfarb, Peter ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Bowel cancer; Chemotherapy; Oxaliplatin; Platinum; ROS (reactive oxygen species)

Indexed keywords

EID: 27744594482     PISSN: 10292659     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Coulson, C. J., Wiseman, A. and King, D. J. (1984) Chemotherapeutic and agrochemical applications of cytochrome P450 inhibitors. Trends in Biochemistry, 15, 100-105.
2. Coulson, C. J. (1994) Molecular Mechanisms of Drug Action (2nd Ed), Taylor & Francis, London, UK.
3. Lewis, D. F. V. (2001) "Guide to Cytochromes P450 Structure and Function" Taylor & Francis, London, UK.
4. Grothey, A. and Goldberg, R. M. (2004) A review of oxaliplati and its clinical use in colorectal cancer. Expert Opinion Pharmacother., 10, 2159-2170.
5. Cheney, N. G., Campbell, M., Temple, R., Bennett, E., Wu, V. and Falda, M. (2004) Protein interactions with platinum-DNA adducts; from structure to function. J. Inorg. Biochem. 10, 1553-1600.
6. Samini, G., Manrock, G., Castel, R., Brenaux, J. K., Cheng, T. C., Berry, C. C., Los, G. and Howell, S. G. (2004) cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance. Cancer Chemother. Pharmacol. 25, 75-80.
7. Andre, T., Boni, C., Moundeji-Boudiaf, I., Navarro, M., Tebernero, J., Hickish, T., Topin, C., Zaninelli, M., Clingan, P Bridgwater, J., Tabah-Finch, I and de Gramont, A. (2004) Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colo-rectal cancer. N Engl. J. Med. 351 (16), 1691-1692.
8. Guglielmi, A., Barni, S., Zaniboni, A., Pella, N., Belvedere, O., Beretta, G. D., Grossi, F., Fronbini, L., Puglini, F., Labianca, R and Sobrero, A. (2004) Phase II study of a triplet regime in advanced colorectal cancer using methotrexate oxaliplatin and 5-fluorouracil. Br. J. Cancer 91 (8), 1428-1433.
9. Calabrese, E. J. and Baldwin, L. A. (2003) Toxicology rethinks its central belief. Nature, 421, 691-692.
10. Halliwell, B. and Gutteridge, J. M. C. (1999) " Free Radicals in Biology and Medicine (3rd ed) ", Clarendon Press, Oxford, UK.
11. Wiseman, H., Goldfarb, P., Ridgway, T. and Wiseman, A. (2000). "Biomolecular Free Radical Toxicity: Causes and Prevention" John Wiley & Sons, Chichester, UK.
12. Abele, D (2002) The radical life-giver. Nature, 420:27.
13. Riedl, A., Shamsi, Z., Anderton, M., Goldfarb, P. S. and Wiseman, A. (1996) Differing features of proteins in membranes may result in antioxidant or pro-oxidant action: opposite effects on lipid peroxidation of alcohol dehydrogenase and albumin in liposome systems. Redox Report, 2, 25-30.
14. Lewis, D. F. V. (2001) " Guide to Cytochromes P450 Structure and Function" Taylor & Francis, London, UK.
15. Wiseman, H. (1994) " Tamoxifen: molecular basis of use in cancer treatment and prevention", John Wiley & Sons, Chichester, UK.
16. Wiseman, A., Ridgway, T. J. and Wiseman, H. (1999) " Added enzymes in the food industry and the future prevention of oxygen radical-mediated damage to food components" in Enzyme Chemistry: impacts and applications eds Suckling, C. J., Gibson, C. and Pitts, A., Blackie & Sons (Chapman & Hall) 2nd Edition, Glasgow, UK. pp 100-125.
17. Wiseman, A. (ed) (1995) " Handbook of Enzyme Biotechnology" (3rd Edition) Ellis Horwood, (Prentice Hall), Hemel Hempstead, UK.
18. Tucker, G. and Woods, L. F. J. (1997) " Enzymes in Food Processing (2nd ed) ", Blackie & Sons, Glasgow, UK.
19. Wiseman, H. (1993) Vitamin D is a membrane antioxidant. Ability to inhibit non chain-breaking dependent lipid peroxidation in liposomes compared to cholesterol, ergosterol and tamoxifen and relevance to anticancer action. FEBS Letts, 326, 285-288.
20. Gamble, S. C., Wiseman, A. and Goldfarb, P. S. (1997) Selenium-dependent glutathione peroxidase and other selenoproteins: their synthesis and biochemical roles. J. Chem. Technol. Biotechnol., 68, 123-134.
21. Wiseman, A., Ridgway, T. J. Goldfarb, P. S., and Woods, L. F. J. (2002) Are food and environmental toxicants "overdetected" by bioassay? Trends in Biotechnology. 20, 13-15.
22. Rayman, M. (2002) Se brought to earth. Chemistry in Britain, 38, 28-31.
23. Wiseman, A. and Woods, L. F. J. (2002) Welcome praise for Copper Chemistry in Britain 38, 20.
24. Brown, D. R. and Sassoon, J. (2002) Copper-dependent functions for the prion protein. Molecular Biotechnology, 22, 165-178.
25. Opara, E. C. (2002) Oxidative stress, micronutrients, diabetes mellitus and its complications. J. Royal Society of Health, 122, 28-34.
26. Wiseman, A. and Woods, L. F. J. (2003) Safe choice of metals in food bioprocess enzyme mimicry? Trends in Biotechnology. 21, 7.
27. Wiseman, A., Lewis, D. F. V., Ridgway, T. J. and Wiseman, H. (2000) Cytochromes P-450 in food-processing: limitations of imitations. J. Chem Technol. Biotechnol. 75, 3-5.
28. Wiseman, A. and Woods, L. F. J. (2002) Precautions against immobilised enzyme (IME) inhibitors Trends in Food Science & Technology 12, 469-470.
29. Wiseman, A., Goldfarb, P. S., Woods, L. F. J. and Ridgway, T. (2001) Novel biocatalytic enzymes by directed evolution. Trends in Biotechnology 19, 382.
30. Wiseman, A. (2003) Toxic residues. Biologist 50, 4.
31. Wiseman, A. (2003) Problems with enzyme bioprocessing of foodstuffs. Trends in Food Science and Technology 14, 109-110.
32. Wiseman A (2003) Limitations of in silico predictability of specificity of co-immobilised cytochromes P450 and mimics in food-bioprocessing. Biotechnology Letters, 25, 515-519.
33. Wiseman A (2003) Biosustainability-limit to industrial biocatalysts if no supersedence of bioprocess perturbation by resilience? Enzyme and Microbial Technology, 32, 635-637.
34. Wiseman, A. and Woods, L. F. J. (2001) Addition of designer enhancers to functional foods: need also for redesigned biocatalysts in fail-clean strategies of bioprocessing? J. Chem. Technol. Biotechnol.; 76, 1038-1040.